Upgrade to SI Premium - Free Trial

Marker Therapeutics (MRKR)

1.07 -0.06 (5.31%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Form 8-K Marker Therapeutics, For: Oct 19 October 19, 2026 7:13 AM - SEC Filing Marker Therapeutics gets $2.6M FDA grant for pancreatic cancer therapy October 19, 2026 7:00 AM - StreetInsider Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer October 19, 2026 7:00 AM - StreetInsider Marker Therapeutics notes expanded CDMO after Kincellis formation September 22, 2026 8:03 AM - StreetInsider Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies September 22, 2026 8:00 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR) August 21, 2026 7:04 AM - StreetInsider Form 10-Q Marker Therapeutics, For: Jun 30 August 14, 2026 4:40 PM - SEC Filing Full Article List